Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dialysis technique tested for better tolerance in kidney patients

NCT ID NCT01327391

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two types of dialysis in 415 older adults (ages 65-90) with chronic kidney failure: online hemodiafiltration and conventional hemodialysis. The goal was to see which method is better tolerated and whether it reduces heart problems and other complications. Patients received three sessions per week for 3-4 hours each. The trial is complete and focused on treatment side effects, quality of life, and cardiovascular outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
online hemodiafiltration (a blood-filtering procedure)
What this could lead to
If online hemodiafiltration proves better tolerated, it could become a preferred dialysis method for older patients with kidney failure, potentially reducing side effects during treatment.
What could go wrong
This is a completed phase 4 trial, so results are already known. The intervention is a variation of standard dialysis, not a breakthrough. Benefits may be modest and not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

415 people

The number who actually took part.

Start date

May 2005

Finished

May 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient who has signed the written consent form * Patient aged \> 65 and \< 90 years * With creatinine clearance \< 10 mL/min * On dialysis for a minimum of 3 months, with 3 times a week hemodialysis sessions * Erythropoietin dosage needed to maintain hemoglobin at a constant level (range of hemoglobin: 9-13 g/dL without any variation of more than 2g/dL for less than 3 months) * Without any problem of vascular access Exclusion Criteria: * Patient aged \< 65 and \> 90 years * Presence of severe malnutrition (albumin \< 20 g/L) * Unstable clinical condition * Unipuncture or failed vascular access flow * Known problems of coagulation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease

Contacts and locations

Locations

  • Centre Hospitalier Universitaire

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.